Langman M J
University Dept. of Therapeutics, Queens Medical Centre, Nottingham, UK.
Scand J Gastroenterol Suppl. 1987;137:67-70. doi: 10.3109/00365528709089766.
Despite generally held beliefs to the contrary, worthwhile improvements in outcome in patients with haematemesis and melaena may be achievable with H2 antagonist or antifibrinolytic treatment.
尽管普遍持相反观点,但使用H2拮抗剂或抗纤维蛋白溶解剂治疗可能会使呕血和黑便患者的病情得到有价值的改善。